Drug Company Files Second Amended Complaint in Case From 2022
In a 2022 case brought against both CBP and the Office of the U.S. Trade Representative, plaintiff Curia Global Inc., a drug development company, once again amended its complaint to remove one of its family companies, Curia Wisconsin, because “the entity is in the process of changing ownership and no longer wishes to join in this action" (Curia Global Inc. v. U.S., CIT # 22-00247).
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
The drug company previously amended its complaint in April to remove another family company, Curia New Jersey, for the same reason.
In its complaint, Curia said it is contesting a Section 301 investigation on Chinese technological and intellectual property practices. The investigation resulted in imposition of a 25% duty on some of Curia’s products.
It argued that USTR had illegally increased duties assessed by a Section 301 action without evidence that the products had burdened or restricted U.S. commerce. It also claimed that the office had failed to provide enough time for the public to comment and have their submissions considered, as well as that it hadn’t adequately explained its rationale for the tariffs.
The complaint still lists Curia Global as a plaintiff, along with Curia New York, Curia Indiana, Curia Massachusetts, Curia Missouri, Curia New Mexico, Curia Bio, and Curia Bio California.